<DOC>
	<DOCNO>NCT00511355</DOCNO>
	<brief_summary>The primary purpose study evaluate effect combine oral contraceptive ( COC ) NOMAC-E2 hemostasis , lipid , carbohydrate metabolism , adrenal function , thyroid function .</brief_summary>
	<brief_title>Effects Hemostasis , Lipids , Carbohydrate Metabolism , Adrenal &amp; Thyroid Function Combined Oral Contraceptive NOMAC-E2 Compared COC Containing LNG-EE ( 292004 ) ( COMPLETED ) ( P05764 )</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Sexually active woman , risk pregnancy planning use trial medication use ; Women need contraception willing use oral contraceptive ( OC ) 6 month ( 6 cycle ) ; At least 18 old 50 year age time screen ; Body mass index = 17 = 29 kg/m^2 ; Good physical mental health ; Willing give informed consent write Present use use within 2 month prior screen hormonal treatment include sex hormone ( contraceptive ) , insulin , thyroid corticosteroid hormone ( exception local dermatological use ) ; Contraindications contraceptive steroid Presence history ( within 1 year screening ) alcohol drug abuse judge ( sub ) investigator . An abnormal cervical smear ( i.e . : dysplasia , cervical intraepithelial neoplasia [ CIN ] , SIL , carcinoma situ , invasive carcinoma ) screen documentation abnormal smear perform within 6 month screen ; Clinically relevant abnormal laboratory result screen judge ( sub ) investigator ; Use injectable hormonal method contraception prior screening ; within 6 month injection 3 month duration , within 4 month screen injection 2month duration , within 2 month injection 1month duration ; Before spontaneous menstruation occur follow delivery abortion ; Breastfeeding within 2 month stop breastfeed prior start trial medication ; Present use use within 2 month prior start trial medication follow drug : phenytoin , barbiturate , primidone , carbamazepine , oxcarbazepine , topiramate , felbamate , rifampicin , nelfinavir , ritonavir , griseofulvin , ketoconazole , lipidlowering drug , anticoagulant herbal remedy contain Hypericum perforatum ( St John 's Wort ) ; Use pharmacological agent affect hemostatic system pretreatment blood sampling : vitamin K ( prohibit within two week prior sample ) , nonsteroidal antiinflammatory drug ( NSAIDS ) aspirin ( prohibit week prior sample ) ; Administration investigational drug and/or participation another clinical trial within 2 month prior start trial medication trial period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>